IFRX
InflaRx NV
NASDAQ · Healthcare · Biotechnology · DE
$1.37
−15.74%Nov 3, 2026, 12:00 UTC
InflaRx N.V. announced an advisory board of international experts in vasculitis, nephrology and immune-mediated renal disease.
Source:Nov 3, 2026, 12:00 UTC
InflaRx N.V. said it plans to initiate a pilot study of izicopan in IgA nephropathy in 2027, with early data expected in 2028.
Source:Nov 3, 2026, 12:00 UTC
InflaRx N.V. announced plans to begin two Phase 2 izicopan trials in ANCA-associated vasculitis in 2027, with initial data expected in 2028.
Source:Nov 3, 2026, 12:00 UTC
InflaRx N.V. reported cash, cash equivalents and marketable securities totaling €153.3 million as of September 30, 2026.
Source:Oct 2, 2026, 11:30 UTC
InflaRx N.V. announced it was selected for a late-breaking poster session presenting pre-clinical data on izicopan at the American Society of Nephrology's Kidney Week 2026 in Denver, Colorado, October 21-25.
Source: